Exicure, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.1M
- Price
- $1.08
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.93%
- Volume
- 7.3K
About
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Quick stats
Shares outstanding6.5M
Computed float4.5M
Float / shares68.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001698530
Websitehttps://www.exicuretx.com
AI Summary
AI-generated1/8
standardbearishregulatory
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
Exicure has been granted a Nasdaq extension through December 2, 2026 to regain compliance with the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1).
The biotech was first notified of the deficiency on June 5, 2026 and also fails the alternative listing standards based on market value of listed securities or net income from continuing operations.
If compliance is not demonstrated by the deadline, Nasdaq may issue a written determination to delist the stock, which Exicure could appeal to a Nasdaq Hearings Panel; the company explicitly notes there is no assurance it will regain or maintain compliance.
Red flags
- Company below Nasdaq minimum stockholders' equity ($2.5M) since June 5, 2026 with no assurance of curing the deficiency
- Hard compliance deadline of December 2, 2026; failure could trigger a written delisting determination
- Company also fails alternative listing standards (market value of listed securities, net income from continuing operations), leaving limited fallback paths
- Extension is not a compliance determination -- elevated risk of future dilutive financing or reverse split to cure equity shortfall